Infliximab (Remicade) Lyophilized Powder from Japan
Infliximab is a chimeric monoclonal antibody against TNF-alpha for psoriasis and ulcerative colitis. HTS 3002.15.00.11 applies to this biotech-derived immunological product in measured retail doses for reconstitution.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Document lyophilization process and monoclonal origin; FDA requires stability post-reconstitution
• Declare as 'immunological product containing monoclonal antibodies' explicitly
• Avoid classifying with general cytokines; specify antibody fraction